Skip to main content

Market Overview

UBS Starts Coverage Of Genesis Healthcare; Time Needed To 'Reposition Balance Sheet'

Share:

In a report published Tuesday, UBS analyst AJ Rice initiated coverage of Genesis Healthcare Inc (NYSE: GEN) with a Neutral rating and $7 price target. The company's experienced management team and its broad and diversified portfolio make it a leader in the national long-term care sector.

On the other hand, with the company being highly leveraged and about 85 percent of its portfolio being leased, the company potentially has limited maneuvering ability. It runs 511 facilities across 34 U.S. states, with 1,569 nursing home-related rehab contracts. About 83 percent of the company's revenues come from skilled nursing, with another 13 percent from rehab services, 2 percent from home health/hospice services and 3 percent from other sources.

Most of Genesis Healthcare's facilities are leased, with only 15 percent facility ownership at present. The analyst expects the company to deliver almost 3 percent core revenue growth in the long term, in the absence of reimbursement cuts and significant divestitures.

"Net income growth should be faster as GEN deploys FCF to reduce debt and also refinances its debt via borrowings from HUDs, which could save the company $14 mln in interest annually," Rice stated.

Latest Ratings for GEN

DateFirmActionFromTo
Jan 2021Credit SuisseDowngradesNeutralUnderperform
Nov 2020Credit SuisseMaintainsNeutral
Nov 2018Stifel NicolausUpgradesHoldBuy

View More Analyst Ratings for GEN
View the Latest Analyst Ratings

 

Related Articles (GEN)

View Comments and Join the Discussion!

Posted-In: AJ Rice UBS VetrAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
ETSYRoth CapitalMaintains245.0
SRTSRoth CapitalMaintains6.0
CZRRoth CapitalMaintains134.0
WWDA DavidsonMaintains33.0
ABNBDA DavidsonMaintains210.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com